Quick Answer
NovoCure Ltd reported Diluted EPS of $1.22 per share (loss) for fiscal year 2025.
NovoCure Ltd Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.22 | +21.8% |
| 2024 | -$1.56 | +20.0% |
| 2023 | -$1.95 | -121.6% |
| 2022 | -$0.88 | -57.1% |
| 2021 | -$0.56 | -411.1% |
| 2020 | $0.18 | +357.1% |
| 2019 | -$0.07 | +89.9% |
| 2018 | -$0.69 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.33 | -17.9% | +8.3% |
| June 30, 2025 | -$0.36 | -16.1% | -16.1% |
| March 31, 2025 | -$0.31 | +13.9% | -10.7% |
| September 30, 2024 | -$0.28 | +39.1% | +9.7% |
| June 30, 2024 | -$0.31 | +42.6% | +13.9% |
| March 31, 2024 | -$0.36 | +28.0% | +21.7% |
| September 30, 2023 | -$0.46 | -84.0% | +14.8% |
| June 30, 2023 | -$0.54 | -134.8% | -8.0% |
- NovoCure Ltd showed an increase of +21.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2018–2025 period, NovoCure Ltd’s diluted eps has declined by 76.8% (from $0.69 per share (loss) to $1.22 per share (loss)).
- The most recent figure is from NovoCure Ltd’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: